Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Anand
Mona
M
Khorashad
Jamshid
J
Marin
David
D
Apperley
Jane F
JF
Goldman
John M
JM
Kaeda
Jaspal Singh
JS
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000008:administration & dosage*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000008:administration & dosage*; D013997:Time Factors; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate